Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrateGIST 3: IDRX-42 versus sunitinib in imatinib-treated advanced GIST
CTR20260348Phase 3Active
- Sponsor
- 不适用/ 葛兰素史克（中国）投资有限公司
- Start
- Apr 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of IDRX-42, sunitinib in gastrointestinal stromal tumor (GIST), sponsored by 不适用/ 葛兰素史克（中国）投资有限公司. Started Apr 2026; status: active.
02
Drugs
IDRX-42sunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on CTR20260348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260348.